Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

698 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2025-04-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer-derived inflammation attenuates the efficacy of adjuvant chemotherapy (CT) in postoperative or metastatic colorectal cancer (mCRC). However, its role in mCRC patients receiving first-line Bevacizumab combined with chemotherapy (Bev/CT) remains unknown. In this prospective observational study, three Bev/CT regimen cohorts (discovery cohort,n=249; Internal validation cohort: n=115; external validation cohort: n=159) and one CT regimen cohort (n=175) were enrolled. Overall survival served as the primary endpoint; clinical response and progression-free survival were secondary endpoints evaluated during follow-up. Investigators used the serum inflammation ratios to evaluate the association between systemic inflammation and clinical outcomes in Bev/CT- and CT-treated mCRC. Combined analysis of 12 cytokines (flow cytometry) and 92 immuno-oncology proteins (Olink) revealed Bev resistance mechanisms and prognosis-predictive biomarkers in Bev/CT treated patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

NCT01912443

Metastatic Colorectal Cancer

UNKNOWN

An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer

NCT01860144

Metastatic Colorectal Cancer

UNKNOWN

Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

NCT04213222

Colon Cancer Rectal Cancer Liver Metastases

UNKNOWN

Evaluation of the Efficacy and Safety of Bevacizumab Combined With PD-1 Monoclonal Antibody in Preoperative Neoadjuvant Therapy for MSS Colorectal Cancer With Liver Metastases

NCT06124729

Colorectal Cancer

NOT_YET_RECRUITING

Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

NCT01554059

Rectal Adenocarcinoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Resistance Bevacizimab Inflamation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of mCRC;
* Aged over 18 years;
* Must be able to receive the further treatment in the hospital.

Exclusion Criteria

* More than two types of malignancies;
* Bacterial or virus infection within one month before diagnosis;
* Taken anti-inflammatory drugs or other forms of chemotherapy before their diagnosis;
* participants whose follow-up was interrupted three months ago without reaching any endpoint.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No